{"title":"Expression and clinical significance of serum microRNA-122 in liver fibrosis of patients with chronic hepatitis B","authors":"Yan Wang, Xiangyu Chen, Ya Li, Yu Wang","doi":"10.3760/CMA.J.ISSN.1000-6680.2018.09.004","DOIUrl":null,"url":null,"abstract":"Objective \nTo evaluate the expression of serum microRNA (miRNA)-122 in patients with chronic hepatitis B (CHB) with different stages of liver fibrosis, and to investigate its relevance with the clinical parameters. \n \n \nMethods \nTotally 138 CHB patients and 30 healthy controls were enrolled. Real-time polymerase chain reaction was used to measure the relative expression of miRNA-122 in serum. Serum levels of ALT, AST, γ-glutamyl-transferase (γ-GT), alkaline phosphatase (ALP), total bilirubin (TBil), albumin, prothrombin time (PT) and HBV DNA were measured, and their correlations with serum miRNA-122 were analyzed. Receiver operating characteristic (ROC)curev analysis was performed for miRNA-122 to compare healthy controls and CHB patients with fibrosis. Non-parametric t-test was used for comparison between groups. \n \n \nResults \nThe relative expressions of serum miRNA-122 in patients with CHB and healthy controls were 4.41±1.32 and 1.47±0.58, respectively, with significantly statistical difference (t=3.16, P 0.05). The area under curve (AUC) value for miRNA-122 in the differentiation between CHB patients and control group was 0.92, and the AUC for predicting significant fibrosis and cirrhosis were 0.78 and 0.81, respectively. \n \n \nConclusion \nSerum miRNA-122 is closely related to the replication of HBV, liver damage and liver fibrosis stage. It may play a suppressive role on the HBV replication and the development of liver fibrosis. \n \n \nKey words: \nLiver cirrhosis; Hepatitis B virus; microRNA-122","PeriodicalId":10127,"journal":{"name":"中华传染病杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华传染病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1000-6680.2018.09.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
To evaluate the expression of serum microRNA (miRNA)-122 in patients with chronic hepatitis B (CHB) with different stages of liver fibrosis, and to investigate its relevance with the clinical parameters.
Methods
Totally 138 CHB patients and 30 healthy controls were enrolled. Real-time polymerase chain reaction was used to measure the relative expression of miRNA-122 in serum. Serum levels of ALT, AST, γ-glutamyl-transferase (γ-GT), alkaline phosphatase (ALP), total bilirubin (TBil), albumin, prothrombin time (PT) and HBV DNA were measured, and their correlations with serum miRNA-122 were analyzed. Receiver operating characteristic (ROC)curev analysis was performed for miRNA-122 to compare healthy controls and CHB patients with fibrosis. Non-parametric t-test was used for comparison between groups.
Results
The relative expressions of serum miRNA-122 in patients with CHB and healthy controls were 4.41±1.32 and 1.47±0.58, respectively, with significantly statistical difference (t=3.16, P 0.05). The area under curve (AUC) value for miRNA-122 in the differentiation between CHB patients and control group was 0.92, and the AUC for predicting significant fibrosis and cirrhosis were 0.78 and 0.81, respectively.
Conclusion
Serum miRNA-122 is closely related to the replication of HBV, liver damage and liver fibrosis stage. It may play a suppressive role on the HBV replication and the development of liver fibrosis.
Key words:
Liver cirrhosis; Hepatitis B virus; microRNA-122